Trial Profile
Open, non-randomised, single centre phase I study to assess the metabolism, excretion and pharmacokinetics of a single oral 100 mg dose of [14C]-AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours refractory to standard treatments
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 12 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 03 Apr 2008 Status change from initiated to recruiting, as reported by clinicaltrials.gov.
- 31 Mar 2008 New trial record.